Novel Technology Enables Encapsulated Cell Therapies Without Triggering Fibrosis

In this podcast, we interviewed Dr. Paul Wotton, CEO, about Sigilon Therapeutics’ discovery platform. The platform combines cell engineering and biocompatible Afibromer™ technology to enable cell therapies that do not trigger fibrosis
View show notes at cellculturedish.com/novel-technology-enables-encapsulated-cell-therapeutics-without-triggering-fibrosis/